LC said Her-Vaxx has shown greater safety signal. It has the same or potential better efficacy.
The other company product makes 7-8B. It has been approved for a long time.
Imugene has a easier runway of what to do Next: Further studies or Discussion with regulator.
Note: Her-Vaxx is a study to treat Gastric Cancer.
Gastric Cancer is mostly common to Asian people.
Imugene's Leslie Chong says positive HER-Vaxx data 'validates entire platform'
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.9¢ |
Change
-0.002(2.82%) |
Mkt cap ! $508.7M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.0¢ | 6.8¢ | $567.8K | 8.218M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 53 | 5889187 | 6.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.9¢ | 376185 | 22 |
View Market Depth
| Last trade - 13.27pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.9¢ |
Change
-0.002 ( 3.09 %) |
||||
| Open | High | Low | Volume | ||
| 7.0¢ | 7.0¢ | 6.8¢ | 4327886 | ||
| Last updated 13.42pm 24/05/2024 ? | |||||
| IMU (ASX) Chart |